Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Suspended 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Basal Cell Nevus Syndrome 3Carcinoma, Basal Cell 2Skin Neoplasms 1

Interventions

HhAntag691 11sonidegib 5cemiplimab 5methyl 5-aminolevulinate 4daromun 4Imiquimod 3IPI-926 3gusacitinib 2Photochemotherapy 2Drug Evaluation 23-ingenyl angelate 2tozuleristide 1silmitasertib 1pembrolizumab 1TAK-441 1NVP-LEQ506 1MAPRE1 protein, human 1Intravital Microscopy 1Interleukin-2 1Injections 1IFL protocol 1Folfox protocol 1Capecitabine 1Bevacizumab 1BO-112 1BMS-833923 1BF-200 ALA 1Ascorbic Acid 1Aminolevulinic Acid 11-phenyl-3,3-dimethyltriazene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Basal Cell × gusacitinib × Clear all
NCT04416516 2024-04-10

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Ascend Biopharmaceuticals Ltd

Phase 2 Completed
21 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

NCT03208296 2023-02-06

Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

Ascend Biopharmaceuticals Ltd

Phase 1/2 Suspended
24 enrolled
Dermatologic

Basal Cell Nevus Syndrome, Carcinoma, Basal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡